Exactly, most BP only have failed NASH trials so far and either no NASH pipeline left or only early stage candidates. I haven’t researched the field recently, but recall ICPT, GALT and VKTX with the most promising late stage pipeline drugs still standing.....and GILD drug failed earlier this year.

$100,000 spent to get an extremely drug to phase 2 in NASH could end with an extremely lucrative ROI in the future.